LABORATORIO FARMAC.ERFO Cash Flow-to-Debt Ratio
LABORATORIO FARMAC.ERFO cash flow-to-debt ratio. LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow-to-Debt Ratio of 0.57x as of December 2023, meaning its operating cash flow of €1.30 Million could theoretically repay 1% of its total liabilities (€2.26 Million) in one year. Check RK7 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LABORATORIO FARMAC.ERFO (2021–2023)
Cash flow-to-debt ratio of LABORATORIO FARMAC.ERFO from 2021 to 2023. Historical debt coverage capacity for LABORATORIO FARMAC.ERFO across 3 annual periods. Check LABORATORIO FARMAC.ERFO investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LABORATORIO FARMAC.ERFO Cash Flow-to-Debt Ratio by Year (2021–2023)
LABORATORIO FARMAC.ERFO cash flow-to-debt ratio by year from 2021 to 2023. Year-by-year debt coverage analysis for LABORATORIO FARMAC.ERFO. For the full cash flow conversion analysis, see LABORATORIO FARMAC.ERFO (RK7) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | 0.57x | €1.30 Million | €2.26 Million | ▲ +691.9% |
| 2022 | 0.07x | €761.80K | €10.53 Million | ▼ -93.0% |
| 2021 | 1.03x | €2.27 Million | €2.21 Million | — |